Search results
Results from the WOW.Com Content Network
Risankizumab, sold under the brand name Skyrizi (/ s k aɪ ˈ r ɪ z i / sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. [6] [7] It is designed to target interleukin 23A (IL-23A). [6] [7] [9] It is given by subcutaneous injection. [6] [7]
A diagram explaining factors affecting arterial pressure. Pathophysiology is a study which explains the function of the body as it relates to diseases and conditions. The pathophysiology of hypertension is an area which attempts to explain mechanistically the causes of hypertension, which is a chronic disease characterized by elevation of blood pressure.
Hypertension, also known as high blood pressure, is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. [11] High blood pressure usually does not cause symptoms itself. [1]
High blood pressure, also called hypertension, is a vicious and smart adversary.It’s vicious because it greatly increases the odds of heart disease and stroke, some of the leading causes of ...
The cause can be an unidentified aneurysm (a spot in the artery that is weak and balloons up to the breaking point). High blood pressure would be the worst-case scenario when there is a weak spot ...
High blood pressure, also known as hypertension, can weaken the heart over time. That may lead to chronic conditions including: That may lead to chronic conditions including: coronary artery disease
The high blood pressure is gradual at early stages and may take at least 10–15 years to fully develop. Besides diabetes, other factors that may also increase high blood pressure include obesity, insulin resistance and high cholesterol levels. In general, fewer than 25 percent of diabetics have good control of their blood pressure. The ...
Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke, heart failure, kidney failure and myocardial infarction. Evidence suggests that a reduction of blood pressure by 5 mmHg can decrease the risk of stroke by 34% and of ischaemic heart disease by 21%.